FINWIRES · TerminalLIVE
FINWIRES

West Pharmaceutical Q1 Non-GAAP Earnings, Net Sales Rise; Issues Q2 Guidance -- Shares Rise Pre-Bell

-- West Pharmaceutical Services (WST) reported Q1 non-GAAP earnings Thursday of $2.13 per diluted share, up from $1.45 a year earlier.

Analysts polled by FactSet expected $1.68.

Net sales for the quarter ended March 31 were $844.9 million, compared with $698 million a year earlier.

Analysts surveyed by FactSet expected $780.3 million.

The company expects Q2 adjusted EPS of $2.05 to $2.12. Analysts surveyed by FactSet expect $2.

Revenue for the quarter is projected to be between $830 million and $850 million. Analysts polled by FactSet expect $818.4 million.

For 2026, the company now expects 2026 adjusted EPS of $8.40 to $8.75, compared with its prior guidance of $7.85 to $8.20. Analysts polled by FactSet expect $8.01.

Revenue for the full-year is now projected to be about $3.30 billion to $3.35 billion, compared with its earlier outlook of $3.22 billion to $3.28 billion. Analysts polled by FactSet expect $3.25 billion.

Shares of the company were over 10% higher in Thursday premarket activity.

Price: $310.00, Change: $+35.59, Percent Change: +12.97%

Related Articles

Mining & Metals

BMO Initiates Coverage of Meridian Mining with an Outperform Rating, C$3.00 Price Target

BMO Capital Markets on Thursday initiated coverage of Meridian Mining (MNO.TO) with an outperform rating and C$3.00 price target.Meridian's Cabacal gold-copper deposit in Brazil stands out as a low-capex, low-complexity, and low-risk project, BMO said.The past-producing mine represents the flagship asset for Meridian and is central to other targets along the Cabacal belt, giving Meridian the opportunity to develop additional assets within the land package, BMO added.Construction is expected to commence in the second quarter of 2027, and Meridian's management is advancing permitting, engineering, and financing milestones, according to BMO.Price: $1.84, Change: $-0.01, Percent Change: -0.54%

$MNO.TO
Australia

Lam Research Likely to Benefit from Healthy Wafer Fabrication Equipment Landscape, RBC Says

Lam Research (LRCX) is likely to benefit from healthy wafer fabrication equipment environment for the next two to three years driven by generative AI demand and memory tightness, RBC Capital Markets said in a Wednesday research report.The brokerage said it raised its fiscal 2026 and 2027 EPS guidance to $5.65 and $7.72, respectively, from $5.30 and $6.84 earlier.The company's fiscal Q3 beat was particularly driven by strength in DRAM and improving NAND outlook amid continued momentum in high bandwidth memory, analysts wrote.China exposure declined during the quarter, and the company expects further declines as global spending accelerates, but overall, China demand remains steady, according to the note.RBC reiterated its outperform rating on the stock and boosted its price target to $310 from $290.Price: $261.88, Change: $-3.68, Percent Change: -1.38%

$LRCX
Asia Markets

Swiss Market Index Recovers; Nestlé, Galderma Shares Rise

The Swiss Market Index broke its three-day losing streak on Thursday, closing 1.38% in the green, amid a busy day of corporate financial updates and private sector data releases.Nestlé (NESN.SW) delivered an organic sales growth of 3.5% year over year in the first quarter, including a negative impact of 90 basis points from the precautionary recall of batches of its infant formula products globally, with total group sales reaching 21.32 billion francs. Real internal growth came in at 1.2% over the period. The consumer goods giant's stock added 5.89% at closing."A widespread, RIG led beat underpins maintained guidance (with consensus currently at the bottom of the range for sales growth guidance). It is good to see coffee back on song after last year's price squeeze, with RIG of 3.5% and organic sales growth of 9.3%," RBC Capital Markets said in a quick take note, describing the results as "impressive."Galderma Group (GALD.SW) also saw its shares rise 6.60% as it reported a "strong" start to the year, with net sales climbing to $1.47 billion in the first quarter from the year-ago $1.13 billion. For full-year 2026, the dermatology company reaffirmed its guidance of net sales growth between 17% and 20% at constant currency, expecting its exposure to US tariffs to remain "manageable."Other Switzerland-listed heavyweights that posted trading updates included pharmaceutical major Roche (RO.SW), testing and certification company SGS (SGSN.SW), and escalators and elevators manufacturer Schindler (SCHP.SW).On the macroeconomic front, Switzerland signed an investment protection agreement with Saudi Arabia during Swiss President Guy Parmelin's official visit to the Middle Eastern country. The deal is set to become effective following completion of internal approval procedures in both countries.Zooming out to the euro area, the seasonally adjusted S&P Global Flash Eurozone Composite PMI Output Index fell to a 17-month low of 48.6 in April from 50.7 in March. The latest reading marks the first time the index dropped below the neutral 50 threshold in 16 months.

$^SSMI$GALD.SW$NESN.SW$RO.SW$SCHP.SW$SGSN.SW